文献速递浆细胞疾病

达雷妥尤单抗在经重度预治疗的AL淀粉样变性患者中产生快速且深度的血液学缓解

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
PubMed 文献 · Blood · 2017-06-14

该回顾性研究纳入25例既往接受过治疗的免疫球蛋白轻链(AL)淀粉样变性患者,接受达雷妥尤单抗16 mg/kg每周1次共8周,随后每2周1次共8剂,之后每4周1次。总体血液学缓解率为76%,其中完全缓解(CR)36%、非常好的部分缓解(VGPR)24%,中位起效时间1个月,治疗耐受性良好。

要点

  • 达雷妥尤单抗在重度预治疗的AL淀粉样变性患者中总体血液学缓解率达76%。
  • 达雷妥尤单抗治疗后CR率为36%,VGPR率为24%,中位起效时间1个月。
  • 即使72%患者有心脏AL受累,治疗仍耐受良好,仅见1-2级输注反应,无3-4级反应。

核心结论

  • 达雷妥尤单抗是一种高效药物,在本队列的重度预治疗AL淀粉样变性患者中产生了快速且深度的血液学缓解,且无意外毒性。

研究设计与样本

  • 回顾性研究,纳入25例连续既往接受过治疗的AL淀粉样变性患者,接受达雷妥尤单抗治疗。
  • 达雷妥尤单抗给药方案为16 mg/kg每周1次共8周,随后每2周1次共8剂,之后每4周1次。
  • 患者既往接受中位3线治疗,仅5例曾达到血液学完全缓解(CR)。

主要发现

  • 总体血液学缓解率为76%,包括CR 36%和非常好的部分缓解(VGPR)24%。
  • 中位起效时间为1个月。
  • 72%的患者有心脏AL受累,治疗仍耐受良好。
  • 15例患者发生1-2级输注反应,未观察到3级或4级反应。

关键数值与推荐

  • 总体血液学缓解率76%,CR率36%,VGPR率24%。
  • 中位起效时间1个月。
  • 1-2级输注反应发生于15例患者,无3级或4级反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually experience hematologic relapse and progression of organ involvement. Additional well-tolerated treatment options are needed. We present our retrospective experience of 25 consecutive previously treated AL patients who received daratumumab, a CD38-directed monoclonal antibody approved for the treatment of multiple myeloma. Daratumumab was administered at 16 mg/kg weekly for 8 weeks, then every 2 weeks for 8 doses, and then every 4 weeks. Patients had received a median of 3 prior lines of therapy, with a previous hematologic CR in only 5 patients. The overall hematologic response rate to daratumumab was 76%, including CR in 36% and very good partial response in 24%. Median time to response was 1 month. Therapy was well tolerated, even among the 72% of patients with cardiac AL involvement. Grade 1-2 infusion reactions occurred in 15 patients, but no grade 3 or 4 reactions were observed. Daratumumab is a highly effective agent that produced rapid and deep hematologic responses without unexpected toxicity in our cohort of heavily pretreated AL patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017. PMID: 28615223. doi:10.1182/blood-2017-01-763599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。